Role of Growth Factors and Biological Response Modifiers in Lung, Head and Neck and Gastrointestinal Tumors

  • G. Stüben
  • M. Stuschke
Part of the Medical Radiology book series (MEDRAD)


The role of growth factors in tumor growth and progression and their usefulness as prognostic and/or predictive factors is a topic of great interest which is reflected by an increasing number of publications over the last few years. These data are briefly summarized in this chapter for a variety of tumors, followed by a discussion of therapeutic approaches that are not covered elsewhere in this book.


Vascular Endothelial Growth Factor Epidermal Growth Factor Receptor Small Cell Lung Cancer Vascular Endothelial Growth Factor Expression Gastrointestinal Tumor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aebersold DM, Froehlich SC, Jonczy M et al (2002) Expression of transforming growth factor-alpha, epidermal growth factor receptor and platelet-derived growth factors A and B in oropharyngeal cancers treated by curative radiation therapy. Radiother Oncol 63:275–283PubMedCrossRefGoogle Scholar
  2. Anderson H, Gurney H, Thatcher N et al (1991) Recombinant human GM-CSF in small cell lung cancer: a phase I/II study. Rec Res Cancer Res 121:155–161CrossRefGoogle Scholar
  3. Antman KS, Griffin JD, Elias A et al (1988) Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med 319:593–598PubMedCrossRefGoogle Scholar
  4. Arnaout AH, Dawson PM, Soomro S et al (1992) HER2 (c-erbB-2) oncoprotein expression in colorectal adeno-carcinoma: an immunohistochemical study using three different antibodies. J Clin Pathol 45:726–727PubMedCrossRefGoogle Scholar
  5. Bennett WP, el-Deiry WS, Rush WL et al (1998) p21waf1/cip1 and transforming growth factor beta 1 protein expression correlate with survival in non-small cell lung cancer. Clin Cancer Res 4:1499–1506PubMedGoogle Scholar
  6. Bitran JD, Green M, Perry M et al (1995) A phase II study of recombinant interferon-gamma following combination chemotherapy for patients with extensive small cell lung cancer. CALGB. Am J Clin Oncol 18:67–70CrossRefGoogle Scholar
  7. Bradley JD, Scott CB, Paris KJ et al (2002) A phase III comparison of radiation therapy with or without recombinant beta-interferon for poor-risk patients with locally advanced non-small-cell lung cancer (RTOG 93-04). Int J Radiat Oncol Biol Phys 52:1173–1179PubMedCrossRefGoogle Scholar
  8. Brattstrom D, Bergqvist M, Hesselius P et al (2002) Elevated preoperative serum levels of angiogenic cytokines correlate to larger primary tumors and poorer survival in non-small cell lung cancer patients. Lung Cancer 37:57–63PubMedCrossRefGoogle Scholar
  9. Brien TP, Odze RD, Sheehan CE et al (2000) HER-2/neu gene amplification by FISH predicts poor survival in Barrett’s esophagus-associated adenocarcinoma. Hum Pathol 31: 35–39PubMedCrossRefGoogle Scholar
  10. Bronchud MH, Scarffe JH, Thatcher N et al (1987) Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer 56:809–813PubMedCrossRefGoogle Scholar
  11. Cascinu S, Graziano F, Catalano V et al (2002) An analysis of p53, BAX and vascular endothelial growth factor expression in node-positive rectal cancer. Br J Cancer 86:744–749PubMedCrossRefGoogle Scholar
  12. Crawford J, Ozer H, Stoller R et al (1991) Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164–170PubMedCrossRefGoogle Scholar
  13. De Vita F, Orditura M, Auriemma A et al (1998) Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer. Oncol Rep 5:649–652PubMedGoogle Scholar
  14. De Vita F, Orditura M, Galizia G et al (2000) Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest 117:365–373PubMedCrossRefGoogle Scholar
  15. Di Carlo A, Mariano A, D'Alessandro V et al (2001) Evaluation of epidermal growth factor receptor, carcinoembryonic antigen and Lewis carbohydrate antigens in human colorectal and liver neoplasias. Oncol Rep 8:387–392Google Scholar
  16. Fontanini G, Faviana P, Lucchi M et al (2001) A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinomas. Br J Cancer 86: 558–563CrossRefGoogle Scholar
  17. Friess H, Wang L, Zhu Z et al (1999) Growth factor receptors are differentially expressed in cancers of the papilla of Vater and pancreas. Ann Surg 230:767–774PubMedCrossRefGoogle Scholar
  18. Gallo O, Masini E, Bianchi B et al (2002) Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma. Hum Pathol 33: 708–714PubMedCrossRefGoogle Scholar
  19. Ghaemmaghami M, Jett JR (1998) New agents in the treatment of small cell lung cancer. Chest 113:86S–91SPubMedCrossRefGoogle Scholar
  20. Gochi A, Orita K, Fuchimoto S et al (2001) The prognostic advantage of preoperative intratumoral injection of OK-432 for gastric cancer patients. Br J Cancer 84:443–451PubMedCrossRefGoogle Scholar
  21. Gunther K, Dworak O, Remke S et al (2002) Prediction of distant metastases after curative surgery for rectal cancer. J Surg Res 103:68–78PubMedCrossRefGoogle Scholar
  22. Gupta AK, McKenna WG, Weber CN (2002) Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res 8:885–892PubMedGoogle Scholar
  23. Han H, Landreneau RJ, Santucci TS et al (2002) Prognostic value of immunohistochemical expression of p53, HER-2/ neu, and bcl-2 in stage I non-small cell lung cancer. Hum Pathol 33:105–110PubMedCrossRefGoogle Scholar
  24. Harari PM, Huang SM (2002) Epidermal growth factor receptor modulation of radiation response: preclinical and clinical development. Semin Radiat Oncol 12:21–26PubMedCrossRefGoogle Scholar
  25. Henke M, Guttenberger R, Barke A et al (1999) Erythropoietin for patients undergoing radiotherapy: a pilot study. Radiother Oncol 50:185–190PubMedCrossRefGoogle Scholar
  26. Homer JJ, Greenman J, Stafford ND (2001) The expression of vascular endothelial growth factor (VEGF) and VEGF-C in early laryngeal cancer: relationship with radioresistance. Clin Otolaryngol 26:498–504PubMedCrossRefGoogle Scholar
  27. Huang SM, Bock JM, Harari PM (1999) Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59:1935–1940PubMedGoogle Scholar
  28. Imdahl A, Bognar G, Schulte-Monting J et al (2002) Predictive factors for response to neoadjuvant therapy in patients with oesophageal cancer. Eur J Cardiothorac Surg 21: 657–663PubMedCrossRefGoogle Scholar
  29. Ito H, Oshita F, Kameda Y et al (2002) Expression of vascular endothelial growth factor and basic fibroblast growth factor in small adenocarcinomas. Oncol Rep 9:119–123PubMedGoogle Scholar
  30. Jett JR, Maksymiuk AW, Su JQet al (1994) Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer. J Clin Oncol 12:2321–2326PubMedGoogle Scholar
  31. Joensuu H, Anttonen A, Eriksson M et al (2002) Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer. Cancer Res 62: 5210–5217PubMedGoogle Scholar
  32. Junker K (2001) Prognostic factors in stage I/II non-small cell lung cancer. Lung Cancer 33[Suppl 1]:S17–S24PubMedCrossRefGoogle Scholar
  33. Karayiannakis AJ, Syrigos KN, Polychronidis A et al (2002) Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery. Ann Surg 236:37–42PubMedCrossRefGoogle Scholar
  34. Kelly K, Crowley JJ, Bunn PA Jr et al (1995) Role of recombinant interferon alfa-2a maintenance in patients with limitedstage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study. J Clin Oncol 13:2924–2930PubMedGoogle Scholar
  35. Khan AJ, King BL, Smith BD et al (2002) Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma. Clin Cancer Res 8:540–548PubMedGoogle Scholar
  36. Knoll MR, Rudnitzki D, Sturm J et al (2001) Correlation of postoperative survival and angiogenic growth factors in pancreatic carcinoma. Hepatogastroenterology 48: 1162–1165PubMedGoogle Scholar
  37. Kristensen CA, Jensen PB, Poulsen HS et al (1996) Small cell lung cancer: biological and therapeutic aspects. Crit Rev Oncol Hematol 22:27–60PubMedCrossRefGoogle Scholar
  38. Laack E, Kohler A, Kugler C et al (2002) Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small cell lung cancer. Ann Oncol 13:1550–1557PubMedCrossRefGoogle Scholar
  39. Landriscina M, Cassano A, Ratto C et al (1998) Quantitative analysis of basic fibroblast growth factor and vascular endothelial growth factor in human colorectal cancer. Br J Cancer 78:765–770PubMedCrossRefGoogle Scholar
  40. Lee DY, Kim SJ, Lee YC (1999) Serum insulin-like growth factor (IGF)-1 and IGF-binding proteins in lung cancer patients. J Korean Med Sci 14:401–404PubMedGoogle Scholar
  41. Lennard CM, Patel A, Wilson J et al (2001) Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. Surgery 129:552–558PubMedCrossRefGoogle Scholar
  42. Liu DH, Zhang XY, Fan DM et al (2001) Expression of vascular endothelial growth factor and its role in oncogenesis of human gastric carcinoma. World J Gastroenterol 7: 500–505PubMedGoogle Scholar
  43. Mall JW, Schwenk W, Philipp AW et al (2002) Serum vascular endothelial growth factor levels correlate better with tumor stage in small cell lung cancer than albumin, neuron-specific enolase or lactate dehydrogenase. Respirology 7: 99–102PubMedCrossRefGoogle Scholar
  44. Masuda N, Fukuoka M, Furuse K (1992) CODE chemotherapy with or without recombinant human granulocyte colony-stimulating factor in extensive-stage small cell lung cancer. Oncology 49[Suppl 1]: 19–24PubMedCrossRefGoogle Scholar
  45. Mattson K, Niiranen A, Pyrhonen S et al (1992) Natural interferon alfa as maintenance therapy for small cell lung cancer. Eur J Cancer 28A:1387–1391PubMedCrossRefGoogle Scholar
  46. Maurizi M, Almadori G, Ferrandina G et al (1996) Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br J Cancer 74: 1253–1257PubMedCrossRefGoogle Scholar
  47. Minami K, Saito Y, Imamura H et al (2002) Prognostic significance of p53, Ki-67, VEGF and Glut-1 in resected stage I adenocarcinomas of the lung. Lung Cancer 38:51–55PubMedCrossRefGoogle Scholar
  48. Mineta H, Miura K, Ogino T et al (2002) Vascular endothelial growth factor (VEGF) expression correlates with p53 and ki-67 expressions in tongue squamous cell carcinoma. Anticancer Res 22:1039–1044PubMedGoogle Scholar
  49. Mouritzen C (1990) Bestatin as adjuvant treatment in operated stage I and stage II non-small cell lung cancer. European Lung Cancer Study Group. Acta Oncol 29:817–820PubMedCrossRefGoogle Scholar
  50. Mukai M, Morita S, Tsunemoto H (1992) Combination therapy of local administration of OK-432 and radiation for esophageal cancer. Int J Radiat Oncol Biol Phys 22:1047–1050PubMedCrossRefGoogle Scholar
  51. Nakayama Y, Sato T, Shibao K et al (2002) Prognostic value of plasma vascular endothelial growth factor in patients with colorectal cancer. Anticancer Res 22:2437–2442PubMedGoogle Scholar
  52. Nieder C, Petersen S, Petersen C et al (2001) The challenge of p53 as prognostic and predictive factor in Hodgkin’s or non-Hodgkin’s lymphoma. Ann Hematol 80:2–8PubMedCrossRefGoogle Scholar
  53. Niedergethmann M, Hildenbrand R, Wostbrock B et al (2002) High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas. Pancreas 25:122–129PubMedCrossRefGoogle Scholar
  54. O’Byrne KJ, Cox G, Swinson D et al (2001) Towards a biological staging model for operable non-small cell lung cancer. Lung Cancer 34[Suppl 2]:S83–S89PubMedCrossRefGoogle Scholar
  55. Paccagnella A, Favaretto A, Riccardi A et al (1993) Granulocyte-macrophage colony-stimulating factor increases dose intensity of chemotherapy in small cell lung cancer. Relationship between clinical results, peripheral blood cell modifications, and bone marrow kinetics. Cancer 72: 697–706PubMedCrossRefGoogle Scholar
  56. Piyathilake CJ, Frost AR, Manne U et al (2002) Differential expression of growth factors in squamous cell carcinoma and precancerous lesions of the lung. Clin Cancer Res 8: 734–744PubMedGoogle Scholar
  57. Potti A, Willardson J, Forseen C et al (2002) Predictive role of HER-2/neu overexpression and clinical features at initial presentation in patients with extensive stage small cell lung cancer. Lung Cancer 36:257–261PubMedCrossRefGoogle Scholar
  58. Raben D, Helfrich BA, Chan D et al (2002) ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol 29:37–46PubMedCrossRefGoogle Scholar
  59. Robert F, Ezekiel MP, Spencer SA et al (2001) Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 19: 3234–3243PubMedGoogle Scholar
  60. Safran H, Steinhoff M, Mangray S et al (2001) Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma. Am J Clin Oncol 24:496–499PubMedCrossRefGoogle Scholar
  61. Sartor CI (2000) Biological modifiers as potential radiosen-sitizers: targeting the epidermal growth factor receptor family. Semin Oncol 27:15–20PubMedGoogle Scholar
  62. Scagliotti GV, Novello S (2001) Role of erythropoietin in the treatment of lung cancer associated anaemia. Lung Cancer 34[Suppl 4]:S91–S94PubMedCrossRefGoogle Scholar
  63. Selvaggi G, Scagliotti GV, Torri V et al (2002) HER-2/neu overexpression in patients with radically resected non-small cell lung carcinoma. Impact on long-term survival. Cancer 94:2669–2674PubMedCrossRefGoogle Scholar
  64. Seo Y, Baba H, Fukuda T et al (2000) High expression of vascular endothelial growth factor is associated with liver metastases and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 88:2239–2245PubMedCrossRefGoogle Scholar
  65. Shimada H, Takeda A, Nabeya Y et al (2001) Clinical significance of serum vascular endothelial growth factor in esophageal squamous cell carcinoma. Cancer 92:663–669PubMedCrossRefGoogle Scholar
  66. Shimada H, Hoshino T, Okazumi S et al (2002) Expression of angiogenic factors predicts response to chemoradiotherapy and prognosis of oesophageal squamous cell carcinoma. Br J Cancer 86:552–557PubMedCrossRefGoogle Scholar
  67. Shou Y, Hirano T, Gong Y et al (2001) Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small cell lung cancer. Br J Cancer 85: 1706–1712PubMedCrossRefGoogle Scholar
  68. Takada M, Fukuoka M, Negoro S et al (1990) Combination therapy with bestatin in inoperable lung cancer. A randomized trial. Acta Oncol 29:821–825PubMedCrossRefGoogle Scholar
  69. Takahama M, Tsutsumi M, Tsujiuchi T et al (1998) Frequent expression of the vascular endothelial growth factor in human non-small cell lung cancers. Jpn J Clin Oncol 28: 176–181PubMedCrossRefGoogle Scholar
  70. Thames HD, Petersen C, Petersen S et al (2002) Immunohisto-chemically detected p53 mutations in epithelial tumors and results of treatment with chemotherapy and radiotherapy. A treatment-specific overview of the clinical data. Strahlenther Onkol 178:411–421PubMedCrossRefGoogle Scholar
  71. Umezawa H, Aoyagi T, Suda H et al (1976) Bestatin, an inhibitor of aminopeptidase B, produced by actinomycetes. J Antibiot (Tokyo) 29:97–99CrossRefGoogle Scholar
  72. Volm M, Koomägi R, Mattern J (1999) PD-ECGF, bFGF, and VEGF expression in non-small cell lung carcinomas and their association with lymph node metastasis. Anticancer Res 19:651–656PubMedGoogle Scholar
  73. Wanebo HJ, Jun MY, Strong EW et al (1975) T-cell deficiency in patients with squamous cell cancer of the head and neck. Am J Surg 130:445–451PubMedCrossRefGoogle Scholar
  74. Wang LS, Chow KC, Chi KH et al (1999) Prognosis of esophageal squamous cell carcinoma: analysis of clinicopatho-logical and biological factors. Am J Gastroenterol 94: 1933–1940PubMedCrossRefGoogle Scholar
  75. Werther K, Christensen IJ, Brunner N et al (2000) Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma. Eur J Surg Oncol 26:657–662PubMedCrossRefGoogle Scholar
  76. Wu Y, Yakar S, Zhao L et al (2002) Circulating insulin-like growth factor-1 levels regulate colon cancer growth and metastasis. Cancer Res 62:1030–1035PubMedGoogle Scholar
  77. Yasumitsu T, Ohshima S, Nakano N et al (1990) Bestatin in resected lung cancer. A randomized clinical trial. Acta Oncol 29:827–831PubMedCrossRefGoogle Scholar
  78. Yoshida T, Saeki T, Aoyama Y et al (1997) Treatment of head and neck cancers with BRMs — prolongation of survival. Biotherapy 10:115–120PubMedCrossRefGoogle Scholar
  79. Zalcman G, Tredaniel J, Schlichtholz B et al (2000) Prognostic significance of serum p53 antibodies in patients with limited-stage small cell lung cancer. Int J Cancer 89:81–86PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • G. Stüben
    • 1
  • M. Stuschke
    • 1
  1. 1.Klinik für Strahlentherapie und Radiologische Onkologie der Universität EssenEssenGermany

Personalised recommendations